Sorafenib Combined with TACE in Advanced Primary Hepatocellular Carcinoma
Sorafenib Combined with TACE in Advanced Primary Hepatocellular Carcinoma
复制标题
DOI：
10.5754/hge12552
复制
发表时间：
2013-03-01
影响因子：
--
通讯作者：
Chen, Li
中科院分区：
文献类型：
--
作者：
Cui, Han-zhi;Dai, Guang-hai;Chen, Li
背景/目标：目的评价索拉非尼联合肝动脉化疗栓塞（TACE）治疗中晚期原发性肝癌的疗效和安全性。方法学：回顾性分析了65例接受索拉非尼治疗超过1个月并接受TACE治疗的晚期原发性肝癌患者。根据实体瘤缓解评价标准评价肿瘤缓解，并记录任何副作用。结果：12例患者进入部分缓解，42例进入稳定状态，11例患者疾病进展。疾病控制率和客观消退率分别为83.1%和18.5%。1年生存率为63.1%。在这些病例中，中位总生存时间为17个月，中位进展时间为9个月。不良反应发生率为78.5%，经治疗后大部分缓解。结论：索拉非尼联合TACE治疗中晚期原发性肝癌安全有效。
Background/Aims: To evaluate the effectiveness and safety of sorafenib combined with transarterial chemoembolization (TACE) in patients with advanced primary hepatocellular carcinoma. Methodology: A retrospective analysis of 65 patients with advanced primary hepatocellular carcinoma who had been administered sorafenib for more than one month and treated by TACE was performed. The tumor response was evaluated according to the response evaluation criteria in solid tumors and any side effects were recorded. Results: Twelve patients entered a partial remission, 42 entered a stable condition, and the disease progressed in 11 patients. The disease control and objective regression rates were 83.1% and 18.5%, respectively. The one-year survival rate was 63.1%. Among the cases, the median overall survival time was 17 months, and the median time to progression was 9 months. The overall side effects rate was 78.5% and most were relieved after treatment. Conclusions: Sorafenib combined with TACE is a safe and effective treatment of advanced primary hepatocellular carcinoma.